earnings
confidence high
sentiment positive
materiality 0.65
Vivos Therapeutics reports FY2024 revenue up 9% to $15M; operating loss narrows 35%
Vivos Therapeutics, Inc.
2025-Q1 EPS
reported -$0.45
vs consensus -$0.41
▼ miss
(-10.3%)
- Revenue $15.0M (+9% YoY); product revenue increased 26%; gross profit $9.0M at 60% margin.
- Operating loss reduced 35% to $11.2M from $17.3M; operating expenses down 21%.
- Cash $6.3M; raised $17.9M via four equity transactions including $7.5M from New Seneca Partners.
- FDA 510(k) clearance for DNA appliance to treat moderate-to-severe OSA in children ages 6-17.
- New strategic alliance with Rebis Health; expects 4-6x increase in revenue per case under new distribution model.